Kirill Osipov commented on the recent invalidation of yet another patent of Russian generic producer Nativa

Pharmaceutical Bulletin – one of the largest professional magazines devoted to Russian pharma – published an article on the recent invalidation of yet another patent of Nativa. Nativa is a Russian generic producer, infamous for its involvement in numerous patent infringement cases with the largest originator makers. Nativa’s patent, rendered invalid in the end of January, was for invention claimed to be dependent on the substance patented by Bristol-Myers Squibb and used in the production of Sprycel.

The Head of Legal Department of ARS-Patent Kirill Osipov provided his comments to Pharmaceutical Bulletin on the case and the acute problem of dependent inventions in general.

The full article is available here.

Make an enquiry

Latest News

Ranking IP STARS 2020

2020-06-25

This year ARS-Patent maintained its presence in the exclusive ranking publication IP STARS of the prestigious media Managing IP. The firm has been ...

Read more
ARS-Patent in ranking IAM Patent 1000

2020-06-18

IAM, the world’s leading IP business media platform, has published the results of the IAM Patent 1000 ranking which identifies the top patent practi...

Read more

View all our News

MEET WITH US

Meet with us at 2019 AIPLA Annual Meeting

2019-10-18

Kirill Osipov, the Head of Legal Department at ARS-Patent, will be attending 2019 AIPLA Annual Meeting on October 24-26 in National Harbor, MD, USA. ...

Read more
Meet ARS-Patent at 4th China Pharma Intellectual Property Summit 2019

2019-10-18

Mikhail Khmara, Managing Partner of ARS-Patent and the Head of Patent Department will attend 4th China Pharma IP Summit 2019 (CPIPS 2019) on October 2...

Read more

See all Events

Back top